TriangleVisugromab (NCT07098988)
Visugromab trial for Metastatic Non-Squamous Non-Small Cell Lung Cancer (NCT07098988). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with newly diagnosed metastatic, non-squamous non-small-cell lung cancer without actionable mutations. No previous systemic treatment for metastatic disease is allowed. PD-L1 must be measured; high expressors need a reason against checkpoint-inhibitor treatment alone.
The idea: block GDF-15 with visugromab to help immune cells enter tumors. After a safety lead-in, random assignment adds visugromab or placebo to pembrolizumab, pemetrexed and carboplatin. Infusions occur every three weeks; carboplatin stops after four cycles. Researchers assess tumor response.
This phase 2 study plans 107 patients. CatalYm sponsors 13 recruiting US sites.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.